Cantor Fitzgerald Weighs in on Kura Oncology FY2026 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for Kura Oncology in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($2.44) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

Several other equities analysts have also issued reports on KURA. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Mizuho decreased their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, May 19th. JMP Securities reissued a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a research report on Wednesday, June 4th. Wall Street Zen lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, UBS Group lowered their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.50.

Kura Oncology Price Performance

NASDAQ:KURA traded up $0.08 during mid-day trading on Tuesday, reaching $6.81. The stock had a trading volume of 671,480 shares, compared to its average volume of 1,213,687. The stock has a market capitalization of $589.58 million, a P/E ratio of -2.89 and a beta of 0.40. The firm has a 50 day moving average price of $6.08 and a two-hundred day moving average price of $7.59. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a one year low of $5.41 and a one year high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Barclays PLC increased its holdings in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after buying an additional 84,563 shares during the period. Rhumbline Advisers grew its stake in Kura Oncology by 2.0% in the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after acquiring an additional 1,923 shares during the period. US Bancorp DE grew its position in shares of Kura Oncology by 184.5% in the fourth quarter. US Bancorp DE now owns 22,104 shares of the company's stock valued at $193,000 after purchasing an additional 14,335 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Kura Oncology by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company's stock worth $5,535,000 after buying an additional 10,542 shares in the last quarter. Finally, E Fund Management Co. Ltd. acquired a new position in Kura Oncology in the 4th quarter valued at $90,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.